Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Non-Current Deffered Revenue: 2014-2017

Historic Non-Current Deffered Revenue for Aytu Biopharma (AYTU) over the last 4 years, with Jun 2017 value amounting to $1,451.

  • Aytu Biopharma's Non-Current Deffered Revenue fell 82.34% to $1,451 in Q2 2017 from the same period last year, while for Jun 2017 it was $1,451, marking a year-over-year decrease of 82.34%. This contributed to the annual value of $1,451 for FY2017, which is 82.34% down from last year.
  • According to the latest figures from FY2017, Aytu Biopharma's Non-Current Deffered Revenue is $1,451, which was down 82.34% from $8,215 recorded in FY2016.
  • In the past 5 years, Aytu Biopharma's Non-Current Deffered Revenue ranged from a high of $511,607 in FY2014 and a low of $1,451 during FY2017.
  • In the last 3 years, Aytu Biopharma's Non-Current Deffered Revenue had a median value of $8,215 in 2016 and averaged $145,186.
  • Data for Aytu Biopharma's Non-Current Deffered Revenue shows a maximum YoY tumbled of 98.07% (in 2016) over the last 5 years.
  • Over the past 4 years, Aytu Biopharma's Non-Current Deffered Revenue (Yearly) stood at $511,607 in 2014, then declined by 16.75% to $425,893 in 2015, then plummeted by 98.07% to $8,215 in 2016, then slumped by 82.34% to $1,451 in 2017.